ABSTRACT We analyzed long-term follow-up data accumulated during an 8 year study of survivors of prehospital cardiac arrest. All patients included in this study were DURING THE PAST 15 years. the success of community-based systems for intervention in prehospital cardiac arrest has established a new population of patients -the survivors of prehospital cardiac arrest who require highly specialized medical attention because of the risk of recurrent cardiac arrest.`Survival after cardiac arrest can be measured in three distinct time frames: (1) from the onset of cardiac arrest to hospitalization, (2) from the period of initial in-hospital care to discharge, and (3) as long-term outcome in patients who have been discharged from the hospital. The earli- Presented in part at the 56th Scientific Sessions of The American Heart Association, Anaheim, CA. November, 1983. est available data were discouraging with respect to outcome in each of these periods: a 60% to 70% prehospital mortality rate, a 50% to 60% mortality rate in hospitalized patients (i.e., 10% to 15% of the total prehospital arrest population survived both prehospital and in-hospital care), and a 45% 24 month rate of recurrence of cardiac arrest among posthospital survivors.
DURING THE PAST 15 years. the success of community-based systems for intervention in prehospital cardiac arrest has established a new population of patients -the survivors of prehospital cardiac arrest who require highly specialized medical attention because of the risk of recurrent cardiac arrest.`Survival after cardiac arrest can be measured in three distinct time frames: (1) from the onset of cardiac arrest to hospitalization, (2) from the period of initial in-hospital care to discharge, and (3) as long-term outcome in patients who have been discharged from the hospital. The earli-est available data were discouraging with respect to outcome in each of these periods: a 60% to 70% prehospital mortality rate, a 50% to 60% mortality rate in hospitalized patients (i.e., 10% to 15% of the total prehospital arrest population survived both prehospital and in-hospital care), and a 45% 24 month rate of recurrence of cardiac arrest among posthospital survivors. 1-3 Later studies demonstrated little improvement in prehospital survival, but a marked improvement in the percentage of patients who survived the prehospital phase and were ultimately discharged from the hospital to enter long-term follow-up (from 10% to 15% to 30% to 35%).f7 The present study was designed to estimate current risk for recurrent cardiac arrest during longterm follow-up of patients receiving antiarrhythmic therapy.
Methods
The study population consists of survivors of prehospital cardiac arrest whose initial rhythm recorded by emergency medical system personnel was ventricular fibrillation or sus-CIRCULATIONtained ventricular tachycardia producing the clinical picture of cardiac arrest, and who were admitted directly to Jackson Memorial Hospital alive after successful prehospital resuscitation. Patients who were initially cared for at other hospitals and subsequently referred to our center for tertiary care are excluded from this report. The analysis included only those patients who were admitted to the study between 1975 and 1980 so that there would be adequate follow-up time for the evaluation of outcome. Since one major goal of the study was to evaluate characteristics during follow-up that may influence outcome, patients who could not be followed by our study group because of geographic or other reasons were excluded from the report.
The deployment and response characteristics of the emergency medical systems in the Greater Miami area have been reported previously. 1 5The emergency rescue personnel are able to reach 80% or more of the emergency calls within 4 min of initial contact,' to provide data on initial rhythms, and to institute resuscitative and interventional procedures at the scene of cardiac arrest.', 5. 8 When successfully resuscitated patients arrive at the emergency room of our medical center, continued resuscitative and/or stabilization procedures are carried out. Beginning immediately patients are monitored for arrhythmias, and they are transported to the coronary care unit or medical intensive care unit of the hospital as promptly as possible. The previously reported procedures for monitoring and clinical evaluation of patients and therapeutic measures5 are instituted under the supervision of the research team of the prehospital cardiac arrest research program.
Patients in whom documented new transmural myocardial infarction was the precipitating event for cardiac arrest were not included in the study. This diagnosis required new Q waves on the electrocardiogram, diagnostic enzyme changes, and a history of chest pain before cardiac arrest. No patient had noncardiac precipitating factors, such as severe electrolyte disturbance, drug overdose, or evidence of proarrhythmic drug effects, at the time of initial hospital admission. Only five patients were receiving antiarrhythmic drugs before suffering cardiac arrest (three quinidine; two procainamide).
Informed consent was obtained from the patient or a close family member before any procedure that is not standard clinical practice for survivors of prehospital cardiac arrest was performed. During the period from 1975 to 1980, when the patients in this report were entered into the study, complete cardiac catheterization and coronary angiographic examination were performed after the first hospital admission in consenting patients who were clinically and hemodynamically stable and free of irreversible major central nervous system injury.5 All patients underwent bedside and ambulatory electrophysiologic monitoring, and invasive electrophysiologic studies were performed for the purpose of determining the characteristics of conduction and arrhythmia induction in those patients who were willing to participate in this aspect of the research program. The patients who survived the initial hospitalization were discharged into a longterm outpatient follow-up program designed to study chronic arrhythmias and response to therapy. A special arrhythmia clinic for this purpose provided frequent 24 hr ambulatory recordings, evaluation of antiarrhythmic drug therapy (including serial determinations of plasma levels of antiarrhythmic drugs), and close monitoring of other cardiovascular and general medical problems in the study population.5 Analysis of arrhythmias on ambulatory recordings was carried out both by calculation of mean hourly frequency of ventricular ectopic beats on 24 hr recordings and by grading according to the modified Lown classification (class 1 = .30 ectopic beats/hr; class 2 = >30 ectopic beats/hr; class 3 = multiform; class 4A = couplets; class 4B = salvos; class 5 = R-on-T phenomenon).
Attempts to contact by telephone and/or mail those patients who refused to participate in the study for geographic or other reasons to allow comparison of outcome in survivors who did and did not continue in the long-term follow-up study did not yield sufficient numbers of responses to make comparison meaningful.
The major variables of the study included in the present report are survival statistics, quantitation of chronic arrhythmias, measurement of left ventricular function, and angiographic description of coronary arterial anatomy in the patients who entered the long-term follow-up study. The goals were to determine longterm outcome after cardiac arrest and to evaluate those variables that might affect it. Duration of follow-up was measured in months from the date of the index cardiac arrest to recurrent cardiac arrest, nonsudden death, or last follow-up contact (in long-term survivors). Statistical analyses included t tests for differences between the means of various measurements in survivors and nonsurvivors, regression analysis of the relationship between duration of survival, quantitative parameters of left ventricular function, and/or incidence of arrhythmias, and life en were performed during subsequent hospitalizations. Sixteen patients were considered for cardiac surgery because of anatomic findings and physiologic status -14 for coronary bypass surgery and two for aortic valve replacement. Seven patients underwent coronary bypass procedures and four of these were long-term survivors, one suffered a nonsudden cardiac death, and two died suddenly during the long-term follow-up. The two aortic valve replacements recommended were both carried out, with one patient continuing as a longterm survivor and one dying suddenly 26 months after the index cardiac arrest. Symptoms of congestive heart failure were noted at some time during follow-up in 20 patients (33%). Therapy with digitalis and diuretics was maintained in 53% of the patients, that with digitalis alone in 19% of patients, and that with diuretics alone in 12% of the patients during follow-up. Antiischemic therapy (/3-blockers and/or nitrates) was used at some point during follow-up in 44 (72%) of the patients. Long-term antiarrhythmic therapy is discussed below. NYHA functional classifications at discharge into long-term follow-up after the initial event were class I in 10 patients (16%), class II in 29 (48%), class III in 19 (31%), and class IV in three (5%).
The overall outcome in the 61 patients entering the long-term follow-up program between 1975 and 1980 and followed to 1983 is summarized in table 1. A total of 24 of the 61 patients (39%) have died during followup, and the remainder continued as long-term survivors up to the point of the last follow-up contact. The age at entry and the male/female distribution were not different in the survivor and nonsurvivor groups. Table  1 also lists the length of follow-up in the long-term survivors, and the duration from the index event to death in those patients who died during follow-up. The mean duration of follow-up in the 37 long-term survivors, from the time of the index event to the last point of follow-up, was 59.9 + 19.4 months. In the 24 patients who have died during follow-up, the mean interval from entry to death was 27.5 + 19.7 months.
A separate analysis of outcome was carried out for the 48 patients in the study in whom the cause of cardiac arrest was coronary artery disease. Eighteen of these 48 patients (38%) died during follow-up, and the mean age at entry of those who died was 59.1 + 7.6 years. There were 16 men and two women in the subgroup. None of these values differ significantly from those for the total study population, from those for the long-term survivors in the coronary disease group, or from those for the subgroup of 13 patients in whom the cause of cardiac arrest was other than coronary artery disease.
Causes of death during follow-up. Analysis of the deaths during follow-up of patients entering long-term studies demonstrated that 16 of the 24 deaths (67%) were the result of recurrent cardiac arrest, and the remaining eight were either nonsudden cardiac or noncardiac deaths. In the latter group, three deaths were due to documented acute myocardial infarction, four were due to cardiogenic shock or congestive heart failure, and one was because of cancer. In the subgroup of 16 patients with recurrent cardiac arrest, the mean interval from entry to death was 23.6 ± 19.2 months, with a median interval of 17 months; in the nonsudden death subgroup, the mean interval from entry to death was 35.4 + 19.3 months, with a median interval of 37 months. A t test analyzing the differences between the mean values for duration from entry to recurrent cardiac arrest or to nonsudden cardiac death indicated significance (t = 2.37, p <.05; figure 1). It is noteworthy that 13 FIGURE 1. Causes of death during follow-up. The incidence of death due to recurrent cardiac arrest is compared with that of nonsudden cardiac death/noncardiac death. Sixteen of 24 deaths during the followup period were the result of recurrent cardiac arrest, with a mean interval from entry to death of 23.6 months. In contrast, the remaining eight nonsudden deaths occurred at a mean interval from entry into the study of 35.4 months (p < .05).
within the first 36 months of follow-up. The falloff in risk for recurrent cardiac arrest after the first 36 months (compared with nonsudden deaths) was statistically significant (2 x 2 contingency table, x2 = 4.59, p < .05). In the subgroup of patients with coronary artery disease, 1 1 of the 18 deaths (61 %) were from recurrent cardiac arrest and the remainder were nonsudden deaths. This ratio of recurrent cardiac arrests to nonsudden deaths did not differ significantly from that in the total patient group.
Long-term outcome. Figure 2 illustrates sudden death and total death survival curves for the 1975 to 1983 study population. We observed a 10% rate of recurrence of cardiac arrest during the first year, and a 5% per year rate of recurrent cardiac arrest rate in the second, third, and fourth years of follow-up. Total death rates during the study period (1975 to 1983) were 1 1%, 7%, 9%, and 9% for each of the first 4 years of follow-up. In the subgroup of 48 patients with coronary artery disease, analysis of survival curves revealed 1 and 2 year rates of recurrence of cardiac arrest of 9% and 4%, respectively. Total death rates in this subgroup were 10% and 5% during the first and second years of follow-up. Neither recurrent cardiac arrest rates nor total death rates in the coronary disease subgroup (n = 48) differed significantly from those in the total population (n = 61). Thirty-nine patients in the long-term follow-up population underwent complete hemodynamic and left ventricular and coronary cineangiographic studies during the initial hospitalization after the index event to provide baseline hemodynamic profiles for long-term follow-up studies. The overall hemodynamic and angiographic data during the initial hospitalization have been reported previously for some of the patients in this study.5 Figure 3 illustrates ejection fraction data obtained from left ventricular cineangiograms at the time of entry into the study. The data are displayed with ejection fractions on the ordinate and duration of follow-up on the abscissa. Duration of follow-up is from entry to death in nonsurvivors who died of recurrent cardiac arrests and in nonsurvivors who died nonsudden deaths, and is the duration to last contact in patients who continued as long-term survivors. The mean ejection fraction at the time of entry into the study among the 21 patients who underwent complete hemodynamic studies and were still alive at the last follow-up contact was 45.3 + 13.6%; in the 18 nonsurvivors in whom baseline studies were obtained it was 37.6 + 12.6%. The corresponding figures for the coronary artery disease subgroup were 44.4 ± 13.4% and 36.2 ± 13.3%, not significantly different from those in the total population. Although the ejection fractions in the survivors were somewhat higher than in the nonsurvivors, a t test for differences between the means in survivors and nonsurvivors showed that these differences were not statistically significant in either the total group or the coronary artery disease subgroup. However, the mean ejection fraction in the subgroup of nonsurvivors who had recurrent cardiac arrests (n = 12) was 42.8 ± 9.2%, compared with 24.5 ± 9. 1% in the nonsudden death subgroup (n = 6); these differences were statistically significant (t = 3.96, p < .002). The corresponding figures for the coronary artery disease population were 43.0 ± 10.7% and 22.0 ± 7.5%, and these differences were also highly significant (t = 3.76, p < .003). Regression analysis of the relationships between time to death and ejection fraction revealed that these two variables were independent ( figure 3) .
Left ventricular end-diastolic pressures and cardiac The upper two rows of data compare recurrent cardiac arrest victims and long-term survivors. The differences between frequency of ventricular ectopic activity (VEA) and between the various Lown classifications for the two groups were not statistically significant. The lower two rows of data separate the ambulatory monitor information in long-term survivors into those from tapes recorded within the first 24 months of follow-up and those recorded more than 24 months after entry into the study. There was a tendency for frequency of ventricular ectopy to be higher in the tapes recorded more than 24 months after entry, but the differences did not achieve statistical significance. There was no difference in the distribution of Lown classifications between tapes recorded early and late.
coronary artery disease revealed a pattern similar to that in the overall group, with no significant differences with respect to either frequency or maximum Lown classification of arrhythmias between victims of recurrent cardiac arrest and long-term survivors.
Arrhythmias and antiarrhythmic drug therapy status before recurrent cardiac arrest. Our previous proposal that stable plasma levels of standard class 1 antiarrhythmic drugs might protect against recurrence in survivors of prehospital cardiac arrest was reevaluated in the present analysis with the use of the larger number of events and the longer period of follow-up. Arrhythmia data from the last ambulatory recording in each of the 16 victims of recurrent cardiac arrest and the status of their antiarrhythmic therapy at the time of recurrent cardiac arrests are summarized in tables 3A and 3B. The mean interval from the last ambulatory recording to recurrent cardiac arrest was 3.8 + 6.9 months (range = 6 days to 24 months; median = 21 days). The same broad range of frequencies and peak grades of arrhythmias were present on these last recordings as had been the case for ambulatory recordings throughout the follow-up period. The analysis of data on antiarrhythmic drug therapies revealed that five of the 16 victims of recurrent arrest (31%) had had a drug stopped or changed for reasons other than failure of the therapy within 4 months of the recurrent event. The last plasma levels determined were nil or below our target range in 14 of 16 recurrent arrest victims (87%), and in the other two (13%) they were at an acceptable target level. In contrast, of 34 long-term survivors who (table 4) . A score of 0 was assigned when no antiarrhythmic drug was being taken, and a score of 1 identified plasma levels in the subtherapeutic range (e.g., <4.0 gg/ml for procainamide, <2.3 ,ug/ml for quinidine, <2.0 ,ug/ml for disopyramide). Levels in the lower half of the standard therapeutic range were assigned a score of 2, levels in the upper half, a score of 3, and supratherapeutic levels a score of 4 (e.g., procainamide = >8.0 jg/ml, quinidine = >5.0 ,g/ml, disopyramide = >5.0 ,ug/ml).
The therapeutic strategy was designed to attempt to achieve a steady-state target score of 3 or 4 by dose adjustment. Table 4 lists the mean normalized plasma level scores at the last measurement before recurrent cardiac arrest, scores for total deaths (sudden and nonsudden), and scores for long-term survivors at 24 to 27 months of follow-up and at last follow-up contact. The mean normalized scores were significantly lower in the victims of recurrent cardiac arrest than in long-term survivors, falling below the value for the lower half of the therapeutic range in the recurrent arrest group (table 4). The data were analyzed further to seek any possible differences in the other clinical characteristics of patients with plasma levels below (scores of 0, 1, or 2) and within the target range (scores of 3 or 4), since differing clinical features could contribute to different risks for recurrent cardiac arrest. Table 5 demonstrates that there were no significant differences between the The current death rate that we are reporting approaches the overall risk of death in patients with coronary artery disease and a moderately depressed left ventricular ejection fraction who have not experienced a prehospital cardiac arrest. 12 Prior studies from both Miami' and Seattle2. 3have reported considerably higher rates of recurrent cardiac arrest among survivors of prehospital cardiac arrest -30% at 1 year and 45% cumulative at 2 years. Even though the earlier study in Miami used the same community-based rescue system" 13 and the same base hospital, it still constitutes a historical comparison group. The use of a historical comparison, rather than concurrent controls, is a limiting feature for interpretation of changing outcomes or attributing changes to specific interventions, and prohibits us from making statistical comparisons of outcome. However, since it is now unlikely that a concurrent controlled study can be carried out, the previous outcomes are mentioned as an overview, with appropriate caveats regarding their interpretation.
The absence of a relationship between severity of ejection fraction abnormalities and time to recurrent cardiac arrest and the absence of a significant difference between ejection fractions in victims of recurrent cardiac arrest and in long-term survivors were unexpected findings. The mean ejection fraction data for the total population was abnormal, and the recurent cardiac arrest victims had somewhat lower ejection fractions than did the long-term survivors, but the dif- The intensity and aggressiveness of long-term antiarrhythmic/anti-ischemic therapy used in our current study population make it different from the approaches used in the survivor populations studied from 1970 to 1973.' -3 5' '1 15 In the latter, only 29 patients received long-term antiarrhythmic therapy after discharge.' Those patients uniformly received lower doses of drugs than are used today and were not systematically monitored for adherence to therapy or for measures of effectiveness.'-. ' Although the absence of a concurrent control group prevents definitive conclusions on the specific factor or factors that are responsible for the outcome observed in our present study population, interventions might indeed influence outcome in unselected survivors of prehospital cardiac arrest resulting from ventricular fibrillation or ventricular tachycardia and not associated with acute transmural myocardial infarction. Several different approaches to the longterm antiarrhythmic management of this patient population have now been proposed, including therapy guided by electrophysiologic testing,'7 'x by targeted suppression of specific forms of chronic arrhythmias16
and by adjustment of dose according to plasma level, which is monitored to ensure that target levels are achieved. '°, ' The patients reported here were managed by the latter technique, but each approach must be analyzed in relationship to the others and with consideration of the patient populations in which they will be applied. Our entry cutoff date of 1980 for patients reported in this study is important with respect to therapeutic strategy as well as duration of follow-up. After 1980, based on the reports of others, '7 11 we began to use therapy guided by programmed stimulation studies for those patients in whom sustained ventricular tachycardia or ventricular fibrillation could be induced when they were off of drugs (approximately 30% of the patients),'7 ' 1 while the remaining 70% were still managed by the methods described above. '9 In patients who were started on therapy guided by plasma level monitoring after entry between 1975 and 1980, treatment was maintained by this approach throughout follow-up.
Even though the present results appear encouraging, continued efforts may ultimately define one of the other techniques, a combination of these techniques, or even an approach unrelated to antiarrhythmic drugs to be the best method of long-term management of this unique patient population or its subgroups. In the meantime, the present outcome data indicate there is an achievable goal of a 10% 1 year and 15% cumulative 2 year rate of recurrence of cardiac arrest against which to measure risk in subgroups and to test effectiveness of various methods of intervention in survivors of prehospital cardiac arrest.
